J 2021

miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors

SHARMA, Sonali; Gabriela MLADONICKÁ PAVLASOVÁ; Václav ŠEDA; Kateřina AMRUZ ČERNÁ; Eva VOJÁČKOVÁ et al.

Základní údaje

Originální název

miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors

Autoři

SHARMA, Sonali; Gabriela MLADONICKÁ PAVLASOVÁ; Václav ŠEDA; Kateřina AMRUZ ČERNÁ; Eva VOJÁČKOVÁ; Daniel FILIP; Laura ONDRIŠOVÁ; Veronika ŠANDOVÁ; Lenka KOŠŤÁLOVÁ; Pedro FARIA ZENI; Marek BORSKÝ; Jan OPPELT; Květoslava LIŠKOVÁ; Leoš KŘEN; Andrea JANÍKOVÁ; Šárka POSPÍŠILOVÁ; Stacey M. FERNANDES; Medhat SHEHATA; Laura Z. RASSENTI; Ulrich JAEGER; Michael DOUBEK; Matthew S. DAVIDS; Jennifer R. BROWN; Jiří MAYER; Thomas J. KIPPS a Marek MRÁZ

Vydání

Blood, Washington, DC, American Society of Hematology, 2021, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/21:00120080

Organizace

Středoevropský technologický institut – Masarykova univerzita – Repozitář

DOI

https://doi.org/10.1182/blood.2020005627

UT WoS

000648518900010

EID Scopus

2-s2.0-85105318244

Klíčová slova anglicky

MYC; miR-29; TRAF4; BCR signaling; BCR inhibitor

Návaznosti

LQ1601, projekt VaV. MUNI/A/1395/2019, interní kód Repo. NV18-03-00054, projekt VaV. 802644, interní kód Repo. NCMG II, velká výzkumná infrastruktura.
Změněno: 16. 10. 2024 00:49, RNDr. Daniel Jakubík

Anotace

V originále

B cell receptor (BCR) signaling and T cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can utilize microRNAs (miRNAs) and their targets to modulate microenvironmental interactions in the lymph node niches. To identify miRNA expression changes in the CLL microenvironment, we performed complex profiling of short non-coding RNAs in this context by comparing CXCR4/CD5 intraclonal cell subpopulations (CXCR4dimCD5bright vs. CXCR4brightCD5dim cells). This identified dozens of differentially expressed miRNAs including several that have previously been shown to modulate BCR signaling (miR-155, miR-150, and miR-22), but also other candidates for a role in microenvironmental interactions. Notably, all three miR-29 family members (miR-29a, miR-29b, miR-29c) were consistently down-modulated in the immune niches, and lower miR-29(a/b/c) levels associated with an increased relative responsiveness of CLL cells to BCR ligation, and significantly shorter overall survival of CLL patients. We identified Tumor-Necrosis Factor Receptor-Associated Factor 4 (TRAF4) as a novel direct target of miR-29s and revealed that higher TRAF4 levels increase CLL responsiveness to CD40 activation and downstream NFkB signaling. In CLL, BCR-represses miR-29 expression via MYC, allowing for concurrent TRAF4 upregulation and stronger CD40-NFkB signaling. This regulatory loop is disrupted by "BCR inhibitors" (BTK inhibitor ibrutinib or PI3K inhibitor idelalisib). In summary, we showed for the first time that a miRNA-dependent mechanism acts to activate CD40 signaling/T-cell interactions in a CLL microenvironment and described a novel miR-29-TRAF4-CD40 signaling axis modulated by the BCR activity.
Zobrazeno: 4. 5. 2026 20:05